The role of serum and glucocorticoid-inducible kinase 1 (SGK1) in renal physiology and pathophysiology is reviewed with particular emphasis on recent advances.
Introduction
The serum and glucocorticoid-inducible kinase 1 (SGK1) was originally cloned as an immediate early gene transcriptionally stimulated by serum and glucocorticoids in rat mammary tumor cells [1] . The human isoform has been discovered as a gene upregulated by cell shrinkage [2] . As listed in Table 1 [3- 35] , SGK1 is under transcriptional control of a variety of further stimuli.
The gene encoding human SGK1 has been localized to chromosome 6q23 [36] . Distinct translational isoforms of SGK1 have been disclosed differing in regulation of expression, subcellular localization, and function [37,38 ,39] . The kinase forms dimers by two intermolecular disulfide bonds between Cys258 in the activation loop and Cys193 [40] . SGK kinases were detected in a variety of species, including shark and Caenorhabditis elegans [7] . Yeast expresses two orthologues, Ypk1 and Ypk2, kinases involved in the regulation of endocytosis and required for survival [7] .
Regulation of serum and glucocorticoid-inducible kinase 1 expression and activity
SGK1 expression is virtually ubiquitous [2] , but varies between different cell types, as observed in brain [7, 41, 42] , eye [7] , inner ear [3, 4, 43] , semicircular canal duct epithelium [4] , lung [7, [44] [45] [46] [47] [48] , kidney [7, 49] , liver [7] , intestine [7] , pancreas [7] , and ovary [7] . Moreover, typical expression patterns are found during embryonic as well as postnatal development [41, [50] [51] [52] . The subcellular localization of SGK1 may depend on the functional state of the cell. Activation of SGK1 following exposure of cells to serum has been suggested to trigger importin-a-mediated entry of SGK1 into the nucleus [7] , whereas activation by hyperosmotic shock or glucocorticoids enhances cytosolic localization of the kinase [1] . SGK1 may further localize to the mitochondrial membrane [53, 54] . SGK1 transcription is rapidly regulated by a wide variety of stimulators and inhibitors (Table 1) . Transcription factor-binding sites have been identified in the promoter of the rat SGK1 gene for the glucocorticoid receptor, the mineralocorticoid receptor, the progesterone receptor, the vitamin D receptor (VDR) , the retinoid X receptor (RXR), the farnesoid X receptor (FXR), the sterol regulatory element-binding protein (SREBP), peroxisome proliferator-activated receptor g (PPARg), the cAMP response element-binding protein (CREB), the p53 tumor suppressor protein, the Sp1 transcription factor, the activating protein 1 (AP1), the activating transcription factor 6 (ATF6), the heat shock factor (HSF), reticuloendotheliosis viral oncogene homologue (c-Rel), nuclear factor kB (NFkB), signal transducers and activators of transcription (STAT), transforming growth factor b (TGFb)-dependent transcription factors SMAD3 and SMAD4, and forkhead activin signal transducer (FAST)
SGK1 is activated by the phosphatidylinositol-3-kinase (PI3-kinase) pathway involving the 3-phosphoinositide (PIP3)-dependent kinase (PDK1) [7] . PIP3 is degraded and thus SGK1 activation discontinued by the phosphatase and tensin homologue (PTEN) [55] . SGK1 activation by PDK1 may involve the scaffold protein Na þ / H þ exchanger regulating factor 2 (NHERF2), which mediates the assembly of SGK1 and PDK1 via its postsynaptic density 95, disk large, zona occludens-1 (PDZ) domains and PDK1 interacting fragment (PIF) consensus sequence [7] . Activation of SGK1 by PDK1 may further involve the mammalian target of rapamycin (mTOR) [56,57 ,58,59] and the serine/threonine kinase WNK1 (with no lysine kinase 1) [60 ,61,62] .
PI3-kinase pathway-dependent activation of SGK1 is triggered by insulin, insulin-like growth factor 1 (IGF1), hepatic growth factor (HGF), and follicle stimulating hormone (FSH) [7] . SGK1 can further be activated by bone marrow kinase/extracellular signal-regulated kinase 5 (BK/ERK5) or by p38a [7], by feeding [63] , by an increase in cytosolic Ca 2þ activity with subsequent activation of calmodulin-dependent protein kinase kinase (CaMKK) [7] , and by the small G-protein Rac1 [7] . SGK1 is further activated by neuronal depolarization, cAMP, lithium, oxidation, and adhesion to fibronectin [7]. SGK1 is degraded with a half-life of 30 min [7] . SGK1 may be ubiquitinated [64, 65] by the ubiquitin ligase Nedd4-2 (neuronal precursor cells expressed developmentally downregulated) [66] .
Serum and glucocorticoid-inducible kinase 1-dependent regulation of cellular functions
The SGK1 kinase consensus sequence R-X-R-X-X-(S/T)-phi (X stands for any amino acid, R for arginine, and phi indicates a hydrophobic amino acid) is shared by 440 Molecular cell biology and physiology of solute transport . Phosphorylated Nedd4-2 is bound to 14-3-3 and is thus unable to ubiquitinate its targets [108] [109] [110] [111] . The P355L Nedd4-2 variant, found in patients with end-stage renal disease (ESRD) and arterial hypertension, was shown to be more sensitive to phosphorylation by SGK1 and, accordingly, to exert a weaker negative effect on epithelial Na þ channel (ENaC) [7] . Furthermore, SGK1 may phosphorylate WNK4, a kinase inhibiting ENaC activity [112] . SGK1 may inhibit inducible nitric oxide synthase, and the decreased formation of nitric oxide may then disinhibit ENaC [113] . SGK1 may also be effective through modification of channel or carrier expression [114] . SGK1 may further regulate carriers and channels through activation of the phosphatidylinositol-3-phosphate-5-kinase (PIKfyve) and subsequent formation of PIP2 [95, 115, 116] .
SGK1 phosphorylates and thus inhibits several enzymes, including the ubiquitin ligase Nedd4-2 [7, 66] , the mitogen-activated protein kinase/ERK kinase kinase 3 (MEKK3) [7] , the kinase SEK1 [21] , the B-Raf kinase [7], the phosphomannose mutase 2 [117] , inducible nitric oxide synthase [113] , and the glycogen synthase kinase 3 (GSK3) [7, 118] , which, however, may be regulated by PKB/Akt rather than SGK1 [7].
SGK1 regulates several transcription factors, including the cAMP responsive element-binding protein (CREB) [119] , NFkB [32,120 ,121] , and the forkhead transcription factor FKHR-L1 (FOXO3a) [7, 122] .
SGK1 phosphorylates a variety of further proteins such as the type A natriuretic peptide receptor (NPR-A) [7], Ca 2þ regulated heat-stable protein of apparent molecular mass 24 kDa (CRHSP24) [123] , the adaptor precursor (APP) Fe65 [72] , NDRG1 and NDRG2 [67] , mosinVc [124] , filamin C [7], microtubule-associated protein tau [125] , and huntingtin [7] . In most cases, the functional significance of SGK1-dependent phorphorylation of those proteins is still elusive. A wide variety of functions have, however, been described, which are regulated by SGK1 (Table 3) [126-144,145 ,146,147 ,148,149,150 ] . Most of those functions have been reviewed previously [7] .
In the following sections, the role of SGK1 in the regulation of electrolyte metabolism and blood pressure will be discussed in more detail.
Role of serum and glucocorticoid-inducible kinase 1 in renal function and salt appetite SGK1 stimulates a variety of renal tubular ion channels and transporters ( Specifically, SGK1 participates in the regulation of renal Na þ excretion by aldosterone, insulin, and IGF1 [91, 155] . The effect of aldosterone is only partially dependent on the presence of SGK1 and the effects of aldosterone and SGK1 are additive. In contrast, antidiuretic hormone (ADH) or insulin does not further stimulate ENaC in cells expressing active SGK1 [156] . Experiments in SGK1-knockout (sgk1 À/À ) mice indeed revealed subtle but relevant impairment of renal salt retention [90 ] . In salt replete conditions, arterial blood pressure and renal salt output are similar in sgk1 À/À mice and their wild-type littermates (sgk1 þ/þ ). The maintenance of salt balance and blood pressure requires, however, increased plasma aldosterone levels in sgk1 À/À mice [7] . Under NaCl-deficient diet, NaCl excretion decreases in both sgk1 À/À and sgk1 þ/þ mice; the renal NaCl retention remains, however, insufficient in sgk1 À/À mice, despite an increase in plasma aldosterone concentration, decrease in arterial blood pressure, decrease in glomerular filtration rate, and enhanced proximal tubular Na þ reabsorption [7]. The renal salt loss of sgk1 À/À mice may not be only due to decreased stimulation of ENaC as enhanced ENaC activity has been observed in salt-depleted sgk1 À/À mice [90 ] , presumably as a result of stimulation of ENaC expression by hyperaldosteronism [90 ] . Similarly, despite the lack of SGK1, ENaC activity is enhanced in the colon of sgk1 À/À mice, which is again likely due to hyperaldosteronism [157] . The enhanced renal salt loss despite increased ENaC activity may be due to decreased expression of the NaCl cotransport in early distal tubule [90 ] . Inhibition of ENaC by triamterene leads to excessive, eventually lethal, salt loss in sgk1 À/À but not in sgk1 þ/þ mice, an observation again pointing to a renal transport defect other than ENaC in sgk1 À/À mice [158] . SGK1 is particularly important for the antinatriuretic effect of insulin, which is significantly blunted in sgk1 À/À mice [136] . Renal salt loss does not appear to be more pronounced in mice lacking both SGK1 and SGK3 [159] .
In dehydration, the enhanced medullary osmolarity upregulates the expression of SGK1, which in turn stimulates the expression of the NPR-A, thus sensitizing the epithelial cells to natriuretic peptides and triggering natriuresis [16] . The renal loss of Na þ counteracts hyperosomolarity during water deprivation [16] .
Lack of SGK1 further impairs the ability of the kidney to excrete a K þ load. Despite enhanced plasma levels of aldosterone, which should increase renal K þ excretion, sgk1 À/À mice do not adequately increase the renal K þ excretion following an acute K þ load [7]. Following a chronic K þ load, sgk1 À/À mice enhance renal K þ excretion only upon marked increase in plasma K þ and aldosterone concentrations [7] . SGK1 is further critically important for the effect of insulin on cellular K þ uptake [160] .
The sgk1 À/À mice express significantly less TRPV5 Ca 2þ channels [132] , an observation consistent with a stimulating effect of SGK1 on TRPV5 [7]. However, despite decreased TRPV5 expression, the renal Ca 2þ excretion is decreased in sgk1 À/À mice [132] . The extracellular volume contraction following renal salt loss due to impaired stimulation of NaCl cotransport and ENaC enhances Na þ [7] and presumably Ca 2þ reabsorption in the proximal tubule and in the thick ascending limb of the loop of Henle, thus decreasing renal Ca 2þ excretion. It is noteworthy that inhibition of NaCl cotransport by thiazide diuretics regularly leads to anticalciuria [161] by a mechanism that involves upregulation of proximal tubular Ca 2þ reabsorption [162] .
In normal kidneys, the proximal tubular SGK1 expression is low [7] and SGK1 is thus not considered to participate in the regulation of proximal tubular transport. In diabetic nephropathy, however, SGK1 is expressed throughout the kidney, including proximal renal tubules and thus stimulates renal tubular glucose transport [163 ] . The effect may be due to stimulation of SGLT1 [7] or due to activation of KCNQ1/KCNE1 [7] , which maintains the electrical driving force for electrogenic glucose transport [164] .
SGK1 is expressed in glomerular podocytes [22, 165] and is upregulated in those cells by aldosterone and oxidative stress [20, 22] . Thus, SGK1 may participate in the development of proteinuria during mineralocorticoid excess and inflammation. As a matter of fact, the proteinuria following deoxycorticosterone acetate (DOCA) treatment is significantly blunted in SGK1-knockout mice [133] . The sgk1 À/À mice are, however, not protected against doxorubicin-induced glomerular injury [135] . SGK1-dependent renal salt retention favors the development of edema during treatment with PPARg agonists [166] or in nephrotic syndrome [135] . Furthermore, increased SGK1 expression has been found during ascites formation in cirrhotic rats [167] .
SGK1 not only participates in the regulation of salt excretion but also contributes to the regulation of salt intake [168] . Treatment of animals with the mineralocorticoid DOCA is followed by excessive salt intake in sgk1 þ/þ but not in sgk1 À/À mice. Thus, SGK1 plays a dual role in mineralocorticoid-regulated NaCl homeostasis, stimulating both intake and renal retention of salt. Serum and glucocorticoid-inducible kinase 1 (SGK1) deficiency decreases NaCl cotransport (NCC) and epithelial Na þ channel (ENaC) activity and blunts the stimulation of renal Na þ reabsorption by insulin and aldosterone as well as the stimulation of salt appetite by mineralocorticoids. The extracellular fluid volume (ECV) contraction decreases cardiac output (CO), thus compromising maintenance of mean arterial pressure (MAP) with subsequent stimulation of the renin-angiotensin and aldosterone system. The hyperaldosteronism at least partially reverses the decrease in ENaC, renal outer medullary K þ channel (ROMK), and Na þ /K þ ATPase activity in principal cells. Nevertheless, SGK1 deficiency impairs stimulation of renal K þ excretion during K þ excess. Despite its stimulation of the distal tubular Ca 2þ channel TRPV5, lack of SGK1 leads to anticalciuria due to compensatory stimulation of Na þ (and Ca 2þ ) reabsorption in proximal tubules. (A II ¼ angiotensin II; R ¼ total peripheral vascular resistance).
Role of serum and glucocorticoid-inducible kinase 1 in hypertension, obesity, and metabolic syndrome
The effect of SGK1 on renal salt excretion and salt intake is expected to have an impact on blood pressure control. As a matter of fact, a certain variant of the SGK1 gene [the combined presence of distinct polymorphisms in intron 6 (I6CC) and in exon 8 (E8CC/CT)] is associated with moderately enhanced blood pressure [7] . The gene variant is common, affecting 3-5% of a white population [7] . Although one study failed to detect a correlation of the gene variant with blood pressure in patients with renal failure [7], a subsequent study on more than 4000 individuals confirmed the association of the gene variant with increased blood pressure [169] . This latter study revealed a particularly strong correlation between insulinemia and blood pressure in individuals carrying the SGK1 gene variant unravelling the decisive role of SGK1 in the hypertension paralleling hyperinsulinemia [169] . Hyperinsulinemia by pretreatment with a high-fructose diet [136] or a high-fat diet [137] sensitizes arterial blood pressure to high-salt intake in sgk1 þ/þ but not in sgk1 À/ À mice. This observation underscores the role of SGK1 in insulin-induced antinatriuresis and blood pressure control. Moreover, SGK1 may participate in the hypertensive effects of glucocorticoids [170] . Lack of Nedd4-2 leads to hypertension in mice, thus mimicking overactivity of SGK1 [171] . Beyond the contribution of SGK1 to blood pressure increase in a given individual, maternal SGK1 appears to be critical for the fetal programing of hypertension in the offspring by stress of the mother [172 ] .
As SGK1 is a powerful stimulator of the Na þ coupled glucose transporter SGLT1 [7], the SGK1 gene variant may further stimulate the intestinal glucose absorption. Enhanced SGLT1 activity accelerates intestinal glucose absorption leading to excessive insulin release, fat deposition, and subsequent decrease in plasma glucose concentration triggering repeated glucose uptake and thus obesity [7] . Conversely, inhibitors of SGLT1 have been shown to counteract obesity [7] . Accordingly, the same SGK1 gene variant associated with enhanced blood pressure proved to be associated with increased body mass index [7] . Moreover, this SGK1 gene variant is more prevalent in patients with type 2 diabetes than in individuals without family history of diabetes [173] .
Hypertension, obesity, and susceptibility to develop type II diabetes are hallmarks of metabolic syndrome, which is associated with enhanced morbidity and mortality from cardiovascular disease [7] . Metabolic syndrome and Cushing's syndrome share common clinical features, but the plasma cortisol levels are not typically elevated in metabolic syndrome [7] . The disorder is rather caused by inappropriate activity of a downstream signaling element. To the extent that SGK1 mediates effects of glucocorticoids on blood pressure and body weight, a SGK1 gene variant leading to increased SGK1 activity would trigger glucocorticoid actions without enhanced plasma glucocorticoid concentrations. Metabolic syndrome is further typically associated with enhanced coagulation [7] , which is again stimulated by SGK1 [13] . Taken together, compelling evidence suggests a participation of SGK1 in the pathophysiology of metabolic syndrome.
Conclusion
The SGK1 is a powerful regulator of metabolism, transport, transcription, and enzyme activity and thus participates in the regulation of a wide variety of physiological functions, including epithelial transport, excitability, cell proliferation, and apoptosis. The phenotype of SGK1-knockout mice is mild and, obviously, the function of this kinase is involved in but not critically important for the maintenance of house keeping functions. However, following appropriate challenges, the lack of SGK1 becomes obvious and physiologically or pathophysiologically relevant. SGK1 plays a particularly important role in electrolyte balance, extracellular volume regulation, metabolic syndrome, tumor growth, inflammation, and fibrosing disease.
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